Posts

Psychedelic Business Spotlight - June 17

Psychedelic Business Spotlight – June 17

, ,
This week in psychedelic business news: ARK Invest advances deep dive into psychedelic stocks; Cybin moves closer to clinical trials, and more!
Psychedelic Business Spotlight - May 20

Psychedelic Business Spotlight – May 20

,
This week in psychedelic business news: Another psychedelic merger; an Optimi Health acquisition; and good news for alcohol abuse treatment.
MAPS Navigates Multiple Scandals: Why Health Canada Is Reviewing MDMA TrialsShutterstock

MAPS Navigates Multiple Scandals: Why Health Canada Is Reviewing MDMA Trials

A sexual misconduct scandal, a data scandal, and an elder abuse scandal haunt psychedelics leader MAPS, currently being scrutinized by Health Canada.
Psychedelic Business Spotlight March 11

Psychedelic Business Spotlight- March 11

,
This week in psychedelic business news: Small Pharma prepares big DMT studies; Health Canada approves a psilocybin PTSD study.
How Psychedelic Treatment Through Health Canada’s SAP WorksShutterstock

How Psychedelic Treatment Through Canada’s SAP Works

Two psychedelic industry insiders reflect on the progress and flaws within Health Canada's recent amendment to the Special Access Program.
Psychedelic Business Spotlight - January 21

Psychedelic Business Spotlight – January 21

,
Catch up on some of the biggest psychedelic business developments that unfolded in the last week.
Canada Green Lights Country’s Third Clinical Psilocybin Study

Canada Green Lights Country’s Third Clinical Psilocybin Study

The trial will build on Diamond Therapeutic's previous animal research that demonstrated how non-hallucinogenic doses of psilocybin hold the potential to treat psychiatric disorders, including anxiety and depression.